Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Nausea 2Multiple Myeloma 2Cachexia 2Anorexia 2Weight Loss 1Vomiting 1Squamous Cell Carcinoma of Head and Neck 1Prosthesis Failure 1Opioid-Related Disorders 1Nutrition Disorders 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

Bevacizumab 76Fluorouracil 56Cetuximab 47Leucovorin 44Oxaliplatin 43pembrolizumab 35Irinotecan 34Folfox protocol 24Capecitabine 24HMPL-013 22Specimen Handling 18trifluridine tipiracil drug combination 16Nivolumab 15Blood Specimen Collection 15Panitumumab 14regorafenib 13Magnetic Resonance Spectroscopy 13Trifluridine 12Standard of Care 12Gemcitabine 12Biopsy 12Cisplatin 11sintilimab 10Interviews as Topic 10IFL protocol 10Drug Therapy 10Carboplatin 9tislelizumab 8Trastuzumab 8Cyclophosphamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Colorectal Neoplasms × Olanzapine × Clear all
NCT05705492 2026-01-21

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
66 enrolled
Gastrointestinal

Anorexia, Cachexia, Esophageal Neoplasms, Neoplasms, Colorectal Neoplasms, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡